Hubei Jianxiang Bioscience (revision 48)

Hubei Jianxiang Bioscience Co., Ltd. (trading as HJ; hubeijianxiang.net) is a research-compound supplier trading as HJ from Xianning, Hubei, China, incorporated in 2015, supplying research peptides and raw materials with batch documentation and tracked shipping.^[1][2]

The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.^[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.^[4]

Incorporated in 2015 and based in Xianning, a prefecture-level city in southern Hubei rather than in the provincial capital, the organisation is among the smaller-city entities covered here.^[1] Hubei has a substantial fine-chemicals sector and Xianning sits within its industrial corridor; the organisation's registered scope is in bioscience, which corresponds to its trading activity.^[1]

Purchaser reports frequently note that shipments originate from a different city from the registered address, which is unremarkable — a registered address is a legal fact and a dispatch point is a logistical one — but is recorded because readers regularly ask about the discrepancy.^[5]

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Reports describe lyophilised material in crimped vials with a batch certificate, and packaging that has been consistent across submissions.^[5] Certificates in this set have generally reported purity, appearance and, on the incretin lines, a water figure.^[5][6]

Where a dispatch point differs from a registered address, no inference about manufacturing location follows: the material may be synthesised, filled and dispatched at three different sites, and nothing in the available documentation establishes which.^[2]

The catalogue is close to the sector standard. Documentation on the incretin lines is better than on the bulk lines, the gradient described on most of these articles.^[5]

Submitted reports on HJ material to July 2026 are concentrated on the incretin analogues, with reported area percent figures clustering in the high nineties and, where a water figure accompanied them, purchaser-computed peptide content in the low-to-mid eighties by mass.^[5][6]

A peptide content in the low eighties is not a deficiency: for a lyophilised peptide with a trifluoroacetate counterion and several percent water it is the arithmetically expected figure. It is stated because readers who see a purity figure of 99% and a content figure of 83% on the same certificate frequently take the discrepancy for an error.^[6]

The PeptidePedia tally records 823 self-reported submissions to July 2026. Recurring positive themes are documentation on the incretin lines and consistent packaging; recurring queries rather than complaints concern the dispatch-address discrepancy.^[4] Self-selected; reception rather than quality.^[4]

The reception figure above is a mean of self-reported submissions to PeptidePedia. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:

• Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
• It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
• It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.^[4]

PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.^[4]

The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.^[1]

Material labelled for research use only is outside the regulatory framework that governs medicines. Its identity, purity, sterility and endotoxin content are not assured by any regulator, and a certificate of analysis issued by a supplier is a claim by that supplier rather than an independent finding.^[3][6]

Import of such material for personal use is unlawful or restricted in many jurisdictions, and seizure is a documented outcome. PeptidePedia describes the legal position and does not advise on it.^[3]

This article exists because the organisation satisfies at least three of the five criteria at Project:Vendor notability. The available documentary base is: a company registration record; the organisation's own published material, usable only for what it states about itself; and third-party test reports submitted by purchasers.^[1][2][5]

What is not available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.^[2]

Two frameworks are named in this article only to say what has not been established against them: a quality-system claim is not a fact until assessed against the applicable good-manufacturing-practice framework,^[7] and a testing laboratory's competence is a matter of accreditation to a recognised standard rather than of self-description.^[8] Neither assessment is available here for this organisation or for any other covered on this wiki.

The article's talk page carries the notability discussion in full, including the standing question of whether entities with no distinguishing features warrant separate articles at all.

• Visit HJ

• Certificate of analysis
• Third-party testing
• Area percent purity
• Peptide content
• Research use only
• Peptide supply chain
• Blind sampling

• Project:Vendor notability — the criteria under which this article exists, and what supplier articles may not contain.
• Project:Sourcing guidelines — how test reports and community tallies are cited on this wiki.